Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort

Authors

  • Nicholas E. Power Dalhousie University, Halifax, NS
  • Wassim Kassouf McGill University, Montreal, QC
  • David Bell Dalhousie University, Halifax, NS
  • Armen Aprikian McGill University, Montreal, QC
  • Yves Fradet Laval University, Quebec, QC
  • Louis Lacombe Laval University, Quebec, QC
  • Joseph Chin University of Western Ontario, London, ON
  • Jonathan Izawa University of Western Ontario, London, ON
  • Eric Estey University of Alberta, Edmonton, AB
  • Adrian Fairey University of Alberta, Edmonton, AB
  • Ilias Cagiannos University of Ottawa, Ottawa, ON
  • Jean-Baptiste Lattouf University of Montreal, Montreal, QC
  • D. Drachenberg Saint Boniface General Hospital (Urology), Winnipeg, MB
  • Ricardo Rendon Dalhousie University, Halifax, NS

DOI:

https://doi.org/10.5489/cuaj.119

Abstract

Background: The present study documents the natural history and outcomes of high-risk bladder cancer after radical cystectomy (RC) in patients who did not receive neoadjuvant chemotherapy during a contemporary time period.

Methods: We analyzed 1180 patients from 1993 to 2008 with >pT3N0 or pT0-4N+ bladder cancer who underwent RC ± standard (sLND) or extended (eLND) lymph node dissection from 8 Canadian centres.

Results: Of the 1180 patients, 55% (n = 643) underwent sLND, 34% (n = 402) underwent ePLND and 11% did not undergo a formal LND. Of the total number of patients, 321 (27%) received adjuvant chemotherapy. The median follow-up was 2.1 years (range: 0.6 to 12.9). Overall 30-day mortality was 3.2%. Clinical and pathological stages T3-4 were present in 6.1% and 86.7% of the patients, respectively; this demonstrates a dramatic understaging. Overall survival (OS) at 2 and 5 years was 60% and 43%, respectively. Patients who received adjuvant chemotherapy hada 2- and 5-year disease-specific survival (DSS) of 72% and 57% versus 64% and 51% for those who did not (log-rank p = 0.0039). The 2- and 5-year OS for high-risk node-negative disease was 67%and 52%, respectively, whereas for node-positive patients, the OS was 52% and 32%, respectively (p < 0.001). The OS, DSS and RFS for patients with pN0 were significantly improved compared to those who did not undergo a LND (log-rank p = 0.0035, 0.0241 and 0.0383, respectively).

Interpretation: This series suggests that bladder cancer outcomes inadvanced disease have improved in the modern era. The need for improved staging investigations, use of neoadjuvant chemotherapyand performance of complete LND is emphasized.

Downloads

Download data is not yet available.

Downloads

Published

2012-12-13

How to Cite

Power, N. E., Kassouf, W., Bell, D., Aprikian, A., Fradet, Y., Lacombe, L., Chin, J., Izawa, J., Estey, E., Fairey, A., Cagiannos, I., Lattouf, J.-B., Drachenberg, D., & Rendon, R. (2012). Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. Canadian Urological Association Journal, 6(6), e217–23. https://doi.org/10.5489/cuaj.119

Issue

Vol. 6 No. 6 (2012): CUAJ December

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.